• Publications
  • Influence
The odyssey of marine pharmaceuticals: a current pipeline perspective.
From a global perspective the marine pharmaceutical pipeline remains very active, and now has sufficient momentum to deliver several additional compounds to the marketplace in the near future; this review provides a current view of the pipeline. Expand
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity
The interactions of PM01183 with selected DNA molecules of defined sequence and its in vitro and in vivo cytotoxicity are characterized. Expand
Kahalalide F and ES285: potent anticancer agents from marine molluscs.
A first generation of drugs from the sea undergoing clinical trials, including PharmaMar compounds: Yondelis, Aplidin, kahalalide F, ES285 and Zalypsis, have been isolated. Expand
Lamellarin D: a novel potent inhibitor of topoisomerase I.
We report the identification and characterization of a novel potent inhibitor of DNA topoisomerase I: lamellarin D (LAM-D), initially isolated from a marine mollusk, Lamellaria sp., and subsequentlyExpand
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.
Results suggest that the cell membrane and, in particular, 2-Hydroxylated fatty acid 2-hydroxy palmitic acid to different human cell lines increased their sensitivity to the cytotoxic compound. Expand
Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.
The results indicate that the marine compound Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCzeta activation. Expand
Genetic Diversity and Geographic Population Structure of Bovine Neospora caninum Determined by Microsatellite Genotyping Analysis
The presence of linkage disequilibrium, the co-existence of specific MLGs to individual farms and eBURST MLG relationships suggest a predominant clonal propagation for Spanish N . Expand
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
Preclinical orthotopically perpetuated ovarian tumor grafts are useful tools for drug development, providing hard evidence that lurbinectedin might be a useful therapy in the treatment of EOC by overcoming cisplatin resistance. Expand
Irvalec Inserts into the Plasma Membrane Causing Rapid Loss of Integrity and Necrotic Cell Death in Tumor Cells
FRET experiments demonstrated that Irvalec molecules localize in the cell membrane close enough to each other as to suggest that the compound could self-organize, forming supramolecular structures that likely trigger cell death by necrosis through the disruption of membrane integrity. Expand
DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
The data suggest that trabectedin interacts with an additional non-DNA target to raise an effective antitumor response, and that this interaction is favored through trabectionin-DNA complexes. Expand